Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro

Journal of Nuclear Medicine

Volumn 47, Issue 9, 2006, Pages 1525-1530

  Smith, Tim A D ^a   Sharma, Rituka I ^a   Thompson, Alastair M ^b   Paulin, Fiona E M ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

18F FDG; Cancer; GLUT; Hexokinase; p53

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 10; GLUCOSE TRANSPORTER 8; HEXOKINASE; MESSENGER RNA; PROTEIN P53; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MICROARRAY; DRUG UPTAKE; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; DOWN REGULATION; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FLUORODEOXYGLUCOSE F18; HUMANS; METABOLIC CLEARANCE RATE; RADIOPHARMACEUTICALS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750598394     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wang XW, Vermeulen W, Coursen JD, et al. The XPD and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996;10:1219-1232.
2. Viktorsson K, De Petris L, Lewenson R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005;331:868-880.
3. Ziyaie D, Hupp TR, Thompson AM. P53 and breast cancer. Breast. 2000;9:239-246.
4. Aas T, Geisler S, Eide S, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2003;39:438-446.
5. King TC, Akerley W, Fan AC, et al. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer. 2000;89:769-773.
6. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(suppl):1S-93S.
7. Borst GR, Belderbos JSA, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541.
8. Sasaki R, Komaki R, Macapinlac H, et al. [F-18]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
9. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [F-18]2-deoxy-2-fluoro- Dglucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273-278.
10. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrzzoli S. 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7:953-959.
11. Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of F-18-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med. 2003;44:192-197.
12. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287.
13. Crippa F, Seregni E, Agresti R et al. Association between [F-18]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429-1434.
14. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64:2627-2633.
15. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, posttranslational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 1997;29:339-343.
16. Cordon-Cardo C, Dalbagni G, Saez GT, et al. P53 mutations in human bladder-cancer: genotypic versus phenotypic patterns. Int J Cancer. 1994;56:347-353.
17. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol. 1992;12:5581-5592.
18. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
19. Miccoli L, Oudard S, Sureau F. Poirson F, Dutrillaux B, Poupon MF. Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J. 1996;313:957-962.
20. Whitesell RR, Ardehali H, Beecham JM, et al. Compartmentalization of transport and phosphorylation of glucose in a hepatoma cell line. Biochem J. 2005;386:245-253.
21. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol. 2001;18:247-256.
22. Rogers S, Macheda ML, Docherty SE, et al. Identification of a novel glucose transporter-like protein: GLUT-12. Am J Physiol Endocrinol Metab. 2002;283:E733-E738.
23. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci. 1999;56:285-292.
24. Smith TA. The rate-limiting step for tumor [F-18]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol. 2001;28:1-4.
25. Torizuka T, Zasadny KR, Becker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in-vitro studies. Radiology. 1998;207:767-774.
26. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
27. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters Eur J Nucl Med Mol Imaging. 2002;10:1317-1323.
28. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93:1046-1052.